NCCN Receives $2.2 Million in Research Funding from Astellas and Medivation to Study Enzalutamide in Solid Tumors

The NCCN Oncology Research Program (ORP) received a $2.2-million grant from Astellas Pharma, Inc. and Medivation, Inc. to facilitate studies of enzalutamide in bladder, breast, endometrial, hepatocellular, ovarian, and prostate cancers. FORT WASHINGTON, PA - The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) has been awarded a $2.2-million grant from Astellas Pharma, Inc. and Medivation, Inc. to develop a program to scientifically evaluate and define the cl...
Source: National Comprehensive Cancer Network - Category: Cancer & Oncology Source Type: news